Skip to main content

Table 3 Dose-dependent percentage of non-transfected cell viability after treatment with different concentrations of puromycin for up to 6 days

From: CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation

Puromycin concentration Non-transfected cell viability %
0 μg/mL 100
3 μg/mL 100
6 μg/mL 85
9 μg/mL 30
12 μg/mL 0
15 μg/mL 0